TCCL Archive
Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival
TCCL Archive
Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis
TCCL Archive
Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL
TCCL Archive
Biomarker May Predict Prostate Cancer Metastases
TCCL Archive
Individualized Cancer Vaccines Show 90% Survival at 6 Months
TCCL Archive
Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial
TCCL Archive
Two Phase II Studies of Ibrutinib Deliver High Response Rates
TCCL Archive
NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent
TCCL Archive
Study: BRCA2-Negative Women Could Still Have High Risk
TCCL Archive
Velcade Addition Can Improve Graft-Versus-Host Outcomes
TCCL Archive
NCI CTEP Approved Trials For the Month of December
TCCL Archive
FDA Expands Nexavar Indication To Include Thyroid Cancer
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Unlocking the future of precision medicine:
The untapped power of RNA - Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime - In The Headlines: Wafik El-Deiry on how “America First” means investing in NCI
- An opportunity for Trump: Position U.S. cancer science to lead the world
